These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27846338)

  • 1. An Evolutionary Perspective on Basal Insulin in Diabetes Treatment: Innovations in Insulin: Insulin Degludec U-100 and U-200.
    Philis-Tsimikas A
    J Fam Pract; 2016 Oct; 65(10 Suppl):S14-S22. PubMed ID: 27846338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of insulin degludec in type 1 and type 2 diabetes based on randomized and observational trials.
    Preumont V; Buysschaert M
    Diabetes Metab; 2020 Apr; 46(2):83-88. PubMed ID: 31055056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice--a case-based evaluation.
    Evans M; McEwan P; Foos V
    J Med Econ; 2015 Feb; 18(2):96-105. PubMed ID: 25325179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life experience of patients starting insulin degludec. A multicenter analysis of 1064 subjects from the German/Austrian DPV registry.
    Bohn B; Zimmermann A; Wagner C; Merger S; Dunstheimer D; Kopp F; Gollisch K; Zindel V; Holl RW;
    Diabetes Res Clin Pract; 2017 Jul; 129():52-58. PubMed ID: 28505544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study.
    Nakamura T; Sakaguchi K; So A; Nakajima S; Takabe M; Komada H; Okuno Y; Hirota Y; Nakamura T; Iida K; Kajikawa M; Nagata M; Ogawa W; Seino S
    Diabetologia; 2015 Sep; 58(9):2013-9. PubMed ID: 26044206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real-world patients with type 1 and type 2 diabetes.
    Oya J; Nakagami T; Hasegawa Y; Katamine A; Kondo Y; Babazono T
    J Diabetes Investig; 2021 Nov; 12(11):1983-1991. PubMed ID: 33938149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study).
    Shimoda S; Sato M; Sekigami T; Motoshima H; Yoshimura R; Fukuda K; Matsuo Y; Noda H; Okubo M; Ichimori S; Fujisawa K; Fukunaga M; Araki E;
    J Diabetes Investig; 2016 Sep; 7(5):703-10. PubMed ID: 27181264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
    Meneghini L; Atkin SL; Gough SC; Raz I; Blonde L; Shestakova M; Bain S; Johansen T; Begtrup K; Birkeland KI;
    Diabetes Care; 2013 Apr; 36(4):858-64. PubMed ID: 23340894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
    Gough SC; Bhargava A; Jain R; Mersebach H; Rasmussen S; Bergenstal RM
    Diabetes Care; 2013 Sep; 36(9):2536-42. PubMed ID: 23715753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
    Heise T; Nørskov M; Nosek L; Kaplan K; Famulla S; Haahr HL
    Diabetes Obes Metab; 2017 Jul; 19(7):1032-1039. PubMed ID: 28295934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin glargine using continuous glucose monitoring: A randomized, cross-over, pilot study.
    Onda Y; Nishimura R; Ando K; Takahashi H; Tsujino D; Utsunomiya K
    Diabetes Res Clin Pract; 2016 Oct; 120():149-55. PubMed ID: 27562434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer insulin analogs: advances in basal insulin replacement.
    Zinman B
    Diabetes Obes Metab; 2013 Mar; 15 Suppl 1():6-10. PubMed ID: 23448197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.
    Berard L; MacNeill G
    Can J Diabetes; 2015 Feb; 39(1):4-9. PubMed ID: 25065475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents.
    Philis-Tsimikas A; Del Prato S; Satman I; Bhargava A; Dharmalingam M; Skjøth TV; Rasmussen S; Garber AJ
    Diabetes Obes Metab; 2013 Aug; 15(8):760-6. PubMed ID: 23577643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes].
    Lüdemann J; Milek K; Wilhelm B; Segner A; Jaeckel E
    MMW Fortschr Med; 2014 Oct; 156 Suppl 3():89-97. PubMed ID: 25507175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Evolutionary Perspective on Basal Insulin in Diabetes Treatment: Innovations in Insulin: Insulin Glargine U-300.
    Anderson JE
    J Fam Pract; 2016 Oct; 65(10 Suppl):S23-S28. PubMed ID: 27846339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.
    Zinman B; Fulcher G; Rao PV; Thomas N; Endahl LA; Johansen T; Lindh R; Lewin A; Rosenstock J; Pinget M; Mathieu C
    Lancet; 2011 Mar; 377(9769):924-31. PubMed ID: 21396703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin degludec: overview of a novel ultra long-acting basal insulin.
    Gough SC; Harris S; Woo V; Davies M
    Diabetes Obes Metab; 2013 Apr; 15(4):301-9. PubMed ID: 23240573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Degludec: a novel basal insulin.
    Kalra S; Baruah MP; Niazi AK
    Recent Pat Endocr Metab Immune Drug Discov; 2012 Jan; 6(1):18-23. PubMed ID: 22280221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes.
    Home PD; Meneghini L; Wendisch U; Ratner RE; Johansen T; Christensen TE; Jendle J; Roberts AP; Birkeland KI
    Diabet Med; 2012 Jun; 29(6):716-20. PubMed ID: 22150786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.